In yesterday’s Wall Street session, Motus GI Holdings Inc. (NASDAQ:MOTS) shares traded at $1.02, up 2.01% from the previous session.
MOTS stock price is now -13.51% away from the 50-day moving average and -70.34% away from the 200-day moving average. The market capitalization of the company currently stands at $4.52M.
With the price target of $14.50, Ladenburg Thalmann recently initiated with Buy rating for Motus GI Holdings Inc. (NASDAQ: MOTS). On August 28, 2018, Dougherty & Company recently initiated its ‘Buy’ rating on the stock quoting a target price of $8.
A total of 2.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in MOTS stock. In total, there are 27 active investors with 6.20% ownership of the company’s stock.
On Tuesday morning Motus GI Holdings Inc. (NASDAQ: MOTS) stock kicked off with the opening price of $1.0100. During the past 12 months, Motus GI Holdings Inc. has had a low of $0.68 and a high of $13.00. As of last week, the company has a debt-to-equity ratio of 14.50, a current ratio of 2.80, and a quick ratio of 2.60. The fifty day moving average price for MOTS is $1.1794 and a two-hundred day moving average price translates $3.4388 for the stock.
The latest earnings results from Motus GI Holdings Inc. (NASDAQ: MOTS) was released for Jun, 2022. According to the Diagnostics & Research Company, earnings per share came in at -$1.86, beating analysts’ expectations of -$2.01 by 0.15. This compares to -$2.00 EPS in the same period last year. The company reported revenue of $0.28 million for the quarter, compared to $0.14 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 97.16 percent. For the current quarter, analysts expect MOTS to generate $330k in revenue.
Motus GI Holdings Inc.(MOTS) Company Profile
Motus GI Holdings, Inc., a medical technology company, develops Pure-Vu system, a medical device to facilitate the cleaning of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedure. The company was incorporated in 2016 and is based in Fort Lauderdale, Florida.